

# Advanced breast cancer: diagnosis and treatment: Guideline Update

## 1 Background

The Advanced breast cancer guideline (CG81) was reviewed in 2015 as part of NICE's routine surveillance programme to decide whether the guideline requires updating.

## 2 Surveillance programme findings

The surveillance programme identified new evidence on oestrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2) effect on disease recurrence. The full report can be found [here](#).

## 3 Guideline Update

We are answering the following question:

- In patients (women and men) with advanced breast cancer and ER/PR/HER2 status known in primary tumour, does receptor status change on disease recurrence?

## 4 Guideline Update process

The guideline update will be produced using a standing Committee. NICE are piloting the use of a standing Committee for guideline updates. More information about the pilot can be found here:

[Guideline Updates](#)

Committee meeting dates: 15 November 2016

Consultation dates: 14 December 2016 – 18 January 2017

Expected publication date: 12 April 2017